MOG (35-55): Benchmark Peptide for Experimental Autoimmune Encephalomyelitis

Executive Summary: MOG (35-55) is a truncated peptide from the myelin oligodendrocyte glycoprotein, routinely employed to induce robust EAE in mice, modeling relapsing-remitting multiple sclerosis (MS) (Xu et al., 2025, DOI). It elicits strong T and B cell immune responses, leading to demyelination and neuroinflammation. The peptide is soluble at ≥32.25 mg/mL in water and ≥86 mg/mL in DMSO, but insoluble in ethanol. APExBIO’s MOG (35-55) (SKU A8306) enables dose-dependent and reproducible EAE induction across mouse strains, facilitating mechanistic and therapeutic MS research (APExBIO). The peptide’s activity correlates with increased NADPH oxidase and MMP-9 activity, making it a reliable probe for oxidative stress and extracellular matrix modulation in vivo and in vitro.

Biological Rationale

Multiple sclerosis (MS) is a chronic autoimmune disease characterized by CNS demyelination. Animal models are essential for dissecting pathogenesis and testing interventions. Experimental autoimmune encephalomyelitis (EAE) is the gold-standard animal model for MS (MOG (35-55): Gold-Standard Peptide for Multiple Sclerosis). MOG (35-55) is a 21-amino acid peptide derived from human myelin oligodendrocyte glycoprotein, corresponding to residues 35–55. It is predominantly expressed in the CNS and belongs to the immunoglobulin superfamily. Upon administration, MOG (35-55) reliably induces EAE when emulsified with complete Freund's adjuvant (CFA) in susceptible mouse strains. This recapitulates key clinical and histological features of MS, including relapsing-remitting paralysis and plaque-like demyelination (Xu et al., 2025).

Mechanism of Action of MOG (35-55)

MOG (35-55) acts as a potent antigen, triggering autoantibody production and robust T and B cell responses. It is presented by major histocompatibility complex (MHC) class II molecules, primarily HLA-DR2 in transgenic mice, activating myelin-specific CD4+ T cells. These autoreactive T cells migrate into the CNS, secrete pro-inflammatory cytokines, and recruit macrophages, leading to demyelination. The peptide also upregulates NADPH oxidase and matrix metalloproteinase-9 (MMP-9), implicating oxidative stress and matrix remodeling in EAE (Xu et al., 2025). In vitro, MOG (35-55) decreases protein concentration in a dose-dependent manner, further verifying its immunogenicity (APExBIO).

Evidence & Benchmarks

• MOG (35-55) induces severe chronic EAE in HLA-DR2 transgenic mice and MS-like disease in C57BL/6 mice when administered subcutaneously with CFA (Xu et al., 2025, DOI).
• Typical EAE induction protocols use 50–150 μg MOG (35-55) per mouse, with severity scaling by dose and strain (Data-Driven Solutions for Reliable Autoimmune Encephalomyelitis).
• Oxidative enzyme activity (NADPH oxidase) and MMP-9 are significantly increased in CNS tissues post-MOG (35-55) administration, supporting its role in neuroinflammation (Xu et al., 2025, DOI).
• Stock solutions are soluble at ≥32.25 mg/mL in water and ≥86 mg/mL in DMSO, but insoluble in ethanol, with optimal storage at -20°C desiccated (APExBIO).
• PARP7 inhibition, a research direction enabled by MOG (35-55) EAE models, stabilizes STAT1/STAT2 and ameliorates EAE symptoms, highlighting translational potential (Xu et al., 2025, DOI).

This article extends Optimizing Experimental Autoimmune Encephalomyelitis by providing mechanistic context for MOG (35-55)–induced oxidative and matrix remodeling events, and updates Mechanistic Frontiers and Strategic Imperatives with the latest insights into PARP7–STAT signaling and translational applicability.

Applications, Limits & Misconceptions

MOG (35-55) is the peptide of choice for preclinical MS research, mechanistic autoimmune studies, and neuroinflammation assays. It is routinely used to evaluate genetic, pharmacologic, and immune interventions targeting T cell activation, cytokine signaling, or CNS repair. However, its utility is constrained by strain- and protocol-specific variables, and it is not suitable for modeling all MS subtypes or other demyelinating diseases.

Common Pitfalls or Misconceptions

• MOG (35-55) only models relapsing-remitting MS forms, not progressive or primary progressive MS.
• Protocol sensitivity: EAE induction efficacy is highly dependent on mouse strain, adjuvant, and dosing regimen.
• Not a therapeutic: MOG (35-55) is a research reagent, not a treatment for MS or other diseases.
• Species limitation: Efficacy and immunopathology may not translate to non-murine species or humans.
• Solubility errors: Ethanol must not be used as a solvent; use sterile water or DMSO.

Workflow Integration & Parameters

APExBIO’s MOG (35-55) (SKU A8306) is supplied lyophilized. For best results, prepare a 0.50 mg/mL stock solution in sterile water, with warming and ultrasonic bath treatment to enhance solubility. Avoid repeated freeze–thaw cycles; store aliquots desiccated at -20°C. For EAE induction, emulsify the peptide with CFA and inject subcutaneously at 50–150 μg per mouse, according to the desired disease severity and mouse strain. In vitro, titrate concentrations to assess immune cell activation, NADPH oxidase, or MMP-9 assays. Refer to the official product page for detailed protocols.

Conclusion & Outlook

MOG (35-55) remains the gold standard for autoimmune encephalomyelitis research, enabling reproducible, mechanistic studies of MS-like pathology. The peptide’s reliability is supported by extensive peer-reviewed benchmarks and robust product validation by APExBIO. Its application enables the discovery of novel targets, such as PARP7 and STAT1/STAT2 signaling axes, with direct translational implications for MS therapy (Xu et al., 2025). Future research will benefit from continued protocol optimization and integration with advanced immune and omics profiling.